Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
Esperion (NASDAQ: ESPR) has announced a virtual key opinion leader (KOL) event scheduled for January 22, 2025, at 11:30 a.m. ET. The event will focus on the real-world use of NEXLETOL® and NEXLIZET®, featuring discussions led by LeAnne Bloedon, VP of Clinical Development, and Dr. Patrick Moriarty from The University of Kansas Medical Center.
The webinar will address unmet needs in LDL-Cholesterol management for cardiovascular disease prevention. Esperion's medications are FDA-approved, oral, once-daily, non-statin medicines supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.
The company is also advancing its next-generation program developing ATP citrate lyase inhibitors (ACLYi), focusing on creating highly potent and specific inhibitors with allosteric mechanisms. The event will be accessible via webcast on Esperion's website, with replay available for approximately 90 days.
Esperion (NASDAQ: ESPR) ha annunciato un evento virtuale per i leader di opinione (KOL) programmato per 22 gennaio 2025, alle 11:30 ET. L'evento si concentrerà sull'uso reale di NEXLETOL® e NEXLIZET®, con discussioni condotte da LeAnne Bloedon, VP dello Sviluppo Clinico, e dal Dr. Patrick Moriarty dell'Università del Kansas Medical Center.
Il webinar affronterà le esigenze non soddisfatte nella gestione del colesterolo LDL per la prevenzione delle malattie cardiovascolari. I farmaci di Esperion sono approvati dalla FDA, sono orali, assunti una volta al giorno e non appartengono alla classe delle statine, supportati dallo studio CLEAR Cardiovascular Outcomes che coinvolge quasi 14.000 pazienti.
L'azienda sta anche portando avanti il suo programma di nuova generazione per lo sviluppo di inibitori dell'ATP citrato liasi (ACLYi), concentrandosi sulla creazione di inibitori altamente potenti e specifici con meccanismi alosterici. L'evento sarà accessibile tramite webcast sul sito web di Esperion, con la registrazione disponibile per circa 90 giorni.
Esperion (NASDAQ: ESPR) ha anunciado un evento virtual dirigido a líderes de opinión (KOL) programado para 22 de enero de 2025, a las 11:30 a.m. ET. El evento se centrará en el uso real de NEXLETOL® y NEXLIZET®, con discusiones lideradas por LeAnne Bloedon, VP de Desarrollo Clínico, y el Dr. Patrick Moriarty de la Universidad de Kansas Medical Center.
El seminario web abordará las necesidades no satisfechas en la gestión del colesterol LDL para la prevención de enfermedades cardiovasculares. Los medicamentos de Esperion están aprobados por la FDA, son orales, se toman una vez al día y no son estatinas, y están respaldados por el estudio CLEAR Cardiovascular Outcomes que involucró a casi 14,000 pacientes.
La compañía también está avanzando en su programa de nueva generación que desarrolla inhibidores de la ATP citrato liasa (ACLYi), enfocándose en crear inhibidores altamente potentes y específicos con mecanismos alostéricos. El evento será accesible a través de una transmisión web en el sitio web de Esperion, con una grabación disponible por aproximadamente 90 días.
Esperion (NASDAQ: ESPR)은 2025년 1월 22일 오전 11:30 ET에 예정된 가상 주요 의견 리더(KOL) 행사를 발표했습니다. 이 행사는 NEXLETOL®과 NEXLIZET®의 실제 사용에 초점을 맞추며, Klinikal 개발 부사장인 LeAnne Bloedon과 캔자스 대학교 의과대학의 Patrick Moriarty 박사가 주최하는 논의가 진행됩니다.
이 웨비나에서는 심혈관 질환 예방을 위한 LDL 콜레스테롤 관리에서 충족되지 않은 요구사항을 다룰 것입니다. Esperion의 약물은 FDA 승인을 받았으며, 구강 투여 형태로 하루 한 번 복용하는 비 스타틴 약물로, 거의 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험의 근거로 뒷받침됩니다.
회사는 또한 ATP 시트르산 리오가제 억제제(ACLYi)의 차세대 프로그램을 발전시키고 있으며, 알로스테릭 메커니즘을 가진 매우 강력하고 특정한 억제제를 개발하는 데 집중하고 있습니다. 이 행사는 Esperion의 웹사이트를 통해 웹캐스트로 접근 가능하며, 약 90일 동안 재생할 수 있습니다.
Esperion (NASDAQ: ESPR) a annoncé un événement virtuel pour les leaders d'opinion (KOL) programmé pour le 22 janvier 2025 à 11h30 ET. L'événement se concentrera sur l'utilisation réelle de NEXLETOL® et NEXLIZET®, avec des discussions dirigées par LeAnne Bloedon, VP du développement clinique, et le Dr Patrick Moriarty de l'Université du Kansas Medical Center.
Le webinaire abordera les besoins non satisfaits dans la gestion du cholestérol LDL pour la prévention des maladies cardiovasculaires. Les médicaments d'Esperion sont approuvés par la FDA, oraux, à prendre une fois par jour et ne sont pas des statines, soutenus par l'étude CLEAR Cardiovascular Outcomes impliquant près de 14 000 patients.
L'entreprise avance également son programme de nouvelle génération développant des inhibiteurs de l'ATP citrate lyase (ACLYi), en se concentrant sur la création d'inhibiteurs hautement puissants et spécifiques avec des mécanismes allostériques. L'événement sera accessible par webcast sur le site Web d'Esperion, avec un replay disponible pendant environ 90 jours.
Esperion (NASDAQ: ESPR) hat eine virtuelle Veranstaltung für Meinungsführer (KOL) angekündigt, die für 22. Januar 2025, 11:30 Uhr ET geplant ist. Die Veranstaltung wird sich auf die reale Anwendung von NEXLETOL® und NEXLIZET® konzentrieren und Diskussionen, die von LeAnne Bloedon, VP für klinische Entwicklung, und Dr. Patrick Moriarty von der University of Kansas Medical Center geleitet werden, beinhalten.
Das Webinar wird unerfüllte Bedürfnisse im Management von LDL-Cholesterin zur Prävention von Herz-Kreislauf-Erkrankungen ansprechen. Die Medikamente von Esperion sind von der FDA zugelassen, oral, einmal täglich einzunehmen und gehören nicht zur Klasse der Statine, unterstützt durch die CLEAR Cardiovascular Outcomes-Studie, an der fast 14.000 Patienten beteiligt waren.
Das Unternehmen treibt zudem sein Programm zur Entwicklung von Inhibitoren der ATP-Zitrat-Lyase (ACLYi) der nächsten Generation voran, das sich auf die Schaffung hochwirksamer und spezifischer Inhibitoren mit allosterischen Mechanismen konzentriert. Die Veranstaltung wird über einen Webcast auf der Website von Esperion zugänglich sein, mit einer Wiederholung, die etwa 90 Tage lang verfügbar ist.
- None.
- None.
– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease –
ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe).
The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with:
- Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center.
Registration for the KOL webinar can be found here. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion's KOL event and what topics will be discussed?
What are the key features of Esperion's (ESPR) FDA-approved medications?
What is Esperion's (ESPR) next-generation drug development program?
Who are the key speakers at Esperion's January 2025 KOL event?
